Immune checkpoint inhibitors in pancreatic cancer / 中华内分泌外科杂志
Chinese Journal of Endocrine Surgery
; (6): 441-444, 2019.
Article
in Zh
| WPRIM
| ID: wpr-805306
Responsible library:
WPRO
ABSTRACT
The comprehensive and multiple disciplinary team therapeutic strategies of pancreatic cancer have been accepted as a consensus. Immune checkpoint inhibitors have made great breakthroughs in the treatment of various solid tumors. However, immune checkpoint inhibitors failed to elicit efficacy in patients with pancreatic cancer and how to overcome the immunosuppressive tumor microenvironment may be the crucial event. Combination regimens of immune checkpoint inhibitors with chemotherapy, radiotherapy, and molecular targeted therapy have been underway, but the sample size of the clinical trial was still limited. Considering the current research status and progress of pancreatic cancer, this article further discusses the practical problems of immune checkpoint inhibitors and makes objective evaluation of its value.
Full text:
1
Index:
WPRIM
Language:
Zh
Journal:
Chinese Journal of Endocrine Surgery
Year:
2019
Type:
Article